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The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer
patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/
lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled
and 35 evaluated. The treatment schedule was oxaliplatin (100mgm
 2), 5-FU (400mgm
 2), leucovorin (40mgm
 2) and epirubicin
(60mgm
 2) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles . Response rate and toxicity
were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital
setting. Sixteen of 35 patients (46%) showed an objective response, two complete response and 14 partial response. Median time to
progression was 33 weeks with an overall median survival of 49 weeks. During the study, anaemia grade 3 and neutropenia grade 3
were observed in 9 and 11% of patients respectively. A grade 3 periferic sensorial neuropathy was observed in 6% of patients. No life
threatening or cardiac toxicity was recorded. The regimen used showed anticancer activity against gastric carcinoma, a tolerable
toxicity profile and excellent patient compliance.
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Gastric cancer is the second most frequent tumour worldwide
and one of the most frequent causes of cancer-related deaths.
Although the incidence and mortality for gastric cancer are
decreasing in many countries and in spite of important changes
in the therapeutic options over the last decade, gastric cancer
still represents the second most frequent malignancy in the world
and the fourth in Europe (Parkin et al, 2001), with a poor
prognosis even at an early stage of the disease. Also, patients
with gastric cancer typically present with advanced disease. For
patients presenting with an earlier stage of disease, more than 50%
undergo surgery, but even after a curative resection, 60%
eventually relapse locally or with distant metastases with a median
survival time of 4–6 months, that may improve up to 7–10
months with a chemotherapy regimen. Although early diagnosis is
the mainstay of successful treatment, even if radically treated,
about 50% of patients present a disease relapse or spread within
5 years from diagnosis (Wilke et al, 1991; Wagner et al,
2005). Hence, in locally advanced or metastatic disease, the only
available choice appears to be systemic chemotherapy (Macdonald
et al, 1979; Preusser et al, 1989; Wagner et al, 2005), that
has proved to improve survival compared with supportive
care alone (hazard ratio (HR): 0.39; 95% confidence interval
(CI): 0.28–0.52). Combination therapy regimens were found
more effective than single-agent therapies, particularly 5-fluoro-
uracil (5-FU), (HR: 0.85; 95% CI:0.76–0.96). Among poly-
chemotherapies those containing the combination with cisplatin
(DDP), 5-FU and antracycline derivatives proved more effective
than those without antracyclines (HR: 0.77; 95% CI: 0.62–0.95)
suggesting that polychemotherapy may significantly improve
survival among patients with advanced stage gastric cancer.
Recognition of epirubicin’s (EPI) activity in gastric cancer and
its better toxicity profile, compared with doxorubicin (Launchbury
and Habboubi, 1993), have led to incorporate it into combination
regimens for advanced gastric cancer. In the last decade,
oxaliplatin (L-OHP), a third-generation platinum derivative, has
been found to represent an intriguing alternative to cisplatin, as it
shows a comparable activity but a more favourable global toxicity
profile (Misset et al, 2000). Moreover, because 5-FU is considered a
cornerstone of therapy for gastric cancer, combining it with
L-OHP is logical, and there is considerable evidence of preclinical
synergy between the two agents (Raymond et al, 1998). Clinical
studies with L-OHP–5FU-based regimen reported a high response
rate ranging from 43 to 55% in the treatment of gastric cancer
and an excellent toxicity profile (Al Batran et al, 2004; De Vita
et al, 2005).
On the basis of these data, we designed this phase II study to
determine the response rate and toxicity profile of the combination
chemotherapy of L-OHP–5FU/LV–EPI as first-line treatment in
locally advanced and/or metastatic gastric cancer.
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sPATIENTS AND METHODS
Eligibility
From December 2001 to November 2003, 36 patients with
histologically proven gastric cancer, locally unrecsectable, recur-
rent after surgery or with metastatic localisations entered the
study, after being thoroughly informed of the study design,
benefits and risks according to the guidelines of local ethic
committee and the Declaration of Helsinki Principles, and all of
them signed their consent. All patients had measurable disease
and met the following criteria: performance status (ECOG)p2, life
expectancy of at least 3 months and age p75 years . Laboratory
acceptance parameters included a white blood cell count above
4000cellsml
 1, a haemoglobin level not lower than 9.5gdl
 1,a
platelet count not less than 100000ml
 1, serum transaminase
o3  the upper normal limit (UNL) and bilirubin and creatinine
values of o1.5 UNL. Contraindication to entry included an
active infectious process, an active heart disease, central nervous
system involvement or any concomitant second primary cancer.
Patients who had received previous chemotherapy were also
excluded.
Pretreatment evaluation
History, full-body examination and tumour-related symptoms
were recorded for each patient. Further assessment included vital
sign examination, performance status determination and labora-
tory tests (haematology, blood chemistry and urinalysis). At study
entry the following investigations were obligatory performed: bone
scintigraphy, ECG, echocardiogram with evaluation of ventricular
function, chest X-ray, abdominal ultrasound, computed tomogra-
phy (CT) and, only if indicated, CT scan of the thorax.
Treatment schedule and dose modifications
Oxaliplatin (100mgm
 2), 5-FU (400mgm
 2), LV (40mgm
 2) and
EPI (60mgm
 2) were administered intravenously, on an out-
patient basis. The treatment was repeated every 3 weeks or until
evidence of disease progression, patient refusal or unacceptable
adverse reactions. The overall treatment was programmed over a 6
month period (maximum eight cycles), considering that the risk of
developing severe disturbance of neurologic function is related to
L-OHP neurotoxicity, that generally becomes a clinical problem
when the cumulative dose approximates 800mgm
 2 (Extra et al,
1998). Full doses of the anticancer drugs were given if granulocyte
count was 41500ml and platelet count was 4100000ml. In the
case of grade 2 or more toxicity excepted alopecia, chemotherapy
was discontinued for a week and than restarted after full recovery.
During the study, leukocite-stimulating growth factors were
allowed in patients showing grade 3 or more neutropenia.
Reduction of 25% in all the drugs dose was performed in the
event of a second consecutive occurrence of grade 42 toxicity.
Patients with unsolved grade 2 or more toxicity after two
consecutive treatment delays or experiencing grade 3 and 4
nonhaematological toxicity except alopecia went off study.
Treatment response and toxicity
For evaluation of tumour response, the best objective imaging
technique for the each individual patient was decided following
pretreatment evaluation (either CT scan, ultrasound or conven-
tional X-ray imaging). The same technique was then performed
every 6 weeks by the same investigator and tumour response was
assessed together with a second independent radiologist.
All the patients were thereafter examined the 15th day of every
cycle and before the start of every following cycle. Toxicity and
response rate were assessed and evaluated according to the WHO
criteria (1979).
Statistical methods
According to the optional Simon two-step design, if a minimum
objective response rate 440% was observed in the first 15 patients,
an additional 15 patients were enrolled and if 412 responses were
observed in 30 patients (40%), the regimen was considered active
and submitted for further evaluation (Simon, 1989). The
descriptive statistics were reported as proportions and medians.
Time to disease progression (TTP), was defined as the interval
between initial treatment and the time of disease progression or
death. Survival time was calculated from the date of treatment
initiation until the date of the last follow-up evaluation or death.
TTP and overall survival (OS) were analysed according to the
Kaplan–Meier method (Kaplan and Meier, 1958). The CIs for
response rates, TTP and OS were calculated using methods for
exact binominal CI (Lentner, 1982) . Survivors were censored on
the last date they were known to be alive.
RESULTS
From December 2001 to November 2003 a total of 36 patients (25
male, 10 female patients, age range 39–72 years, mean age 58
years) were enrolled. Among them, one patient denied consent to
undergo the second treatment and dropped out from the study.
Among the 35 patients who completed the study and were
evaluated for the above mentioned parameters, 27 (77%) had a
performance status up to 1. Twenty-four of 35 had undergone
surgery before the study. The large majority of patients had a
metastatic disease (21/36; 58%), with a high prevalence of nodal or
hepatic disease spread (Table 1).
Table 1 Patient characteristics
No. of patients
Enrolled/evaluable 36/35
Gender
Male 25 (70%)
Female 11 (30%)
Age
Mean 58 years
Range 39–72 years
Performance status
Grade 0 9 (25%)
Grade 1 20 (56%)
Grade 2 6 (17%)
Disease stage
Locally advanced or recurrent 15 (42%)
Metastatic 21 (58%)
Number of metastatic sites
1 10 (50%)
2 7 (33%)
3 4 (17%)
Metastasis localisation
Liver 12
Nodes 9
Peritoneal 8
Lung 2
Bone 4
Ovarian 1
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cycles/patient, range 2–8). At the end of the study, two patients
experienced complete response (6%) and 14 partial response
(40%). The overall response rate was 46% (95% CI: 30.2–63.8),
with a median disease-free survival time of 27 weeks (95% CI:
20–31; range 7–104þ).
Among the other patients, 13 patients showed a stable disease
(37%) whereas six patients presented disease progression (17%).
The median time to disease progression was 33 weeks (95% CI:
17–49; range 6–104þ) with a median survival time of 49 weeks
(95% CI: 32—66; range 9–104þ) (Table 2, Figures 1 and 2). The
overall toxicity is depicted in Table 3. The most frequent toxic
therapy effects were haematological (grade 3 toxicity in seven
patients, anaemia in three and neutropenia in four.) Severe
diarrhoea was present in 2 patients. No grade 4 toxicity was
reported. The L-OHP-related peripheral neuropathy appeared to
be mild and reversible in the majority of cases. No severe cardiac
toxicity or death among the patients was recorded during the
study.
DISCUSSION
Gastric cancer remains a major cause of cancer death worldwide,
with a very poor prognosis in patients with advanced disease. Even
though chemotherapy is found to be more beneficial than
supportive care alone in patients with advanced or metastatic
disease, a standard chemotherapy regimen for gastric cancer has
not yet been established. Among antiblastic agents, 5-FU is widely
used, but the poor response in patients with advanced stage
disease suggests its use it in association with other antiblastic
agents. Several combination therapies that have reported satisfac-
tory results in a phase II study were not confirmed in a
randomised controlled context. Recently, L-OHP, a third-genera-
tion DDP-derived molecule, showed to be effective in the treatment
of disease relapse after 5-FU treatment (Machover et al, 1996) with
a reported response rate in gastro-intestinal tract malignancies
ranging from 10 to 20%. The combination of L-OHP with 5-FU has
been found to be effective in advanced stage with a mild to
moderate toxicity (De Vita et al, 2005; Lordick et al, 2005).
Moreover, the use of L-OHP may be helpful in overcoming drug
resistance-related therapy drawbacks as its molecule does not
share the same action mechanism of DDP.
In the present study, we administered in a 3-week-based
regimen the combination of L-OHP–5FU/LV–EPI as first-line
therapy to patients with locally advanced, recurrent or metastatic
gastric cancer. The overall response rate in our patient group was
high, as 16 out of the 35 patients that completed the study had
an objective response (46%), and two of them had a complete
response (6%). The median time to progression was 33 weeks (8.2
months), with an OS of 49 weeks (12.2 months). The high median
survival time did not appear correlated with a priori criteria in
patient selection, as most patients (58%) had a metastatic disease
at the beginning of the study and 60% of these had multiple
metastatic localisations. The results of recent studies using
different DDP- or L-OHP-based regimens reported in Table 4
show that efficacy and tolerability are better than in other studies
using anthracyclines (Macdonald et al, 1979; Preusser et al, 1989;
In Woo et al, 2005). The L-OHP–5FU/LV–EPI regimen was better
tolerated even when compared with other treatment schedules in
which 5-FU is used as a single agent or in combination (Lordick
et al, 2005). Haematological toxicity was characterised by grade 3
Table 2 Response to treatment
Evaluable patients no. 35
Number of cycles 185
Mean cycles/patient 5.3
Range 2–7
CR 2 (6%)
PR 14 (40%)
Stable Disease: 13 (37%)
Progression of disease 6 (17%)
Overall response rate (CR+PR) 16 (46%)
Median time to progression (weeks) 33 (6–104+)
Median response duration (weeks) 27 (7–104+)
Median survival (weeks) 49 (9–104+)
CR¼complete response; PR¼partial response.
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Figure 1 Kaplan–Meier estimates of time to progression among patients
with gastric cancer treated with oxaliplatin, 5-fluorouracil/leucovorin and
epirubicin regimen.
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Figure 2 Kaplan–Meier estimates of OS among patients with gastric
cancer treated with oxaliplatin, 5-fluorouracil/leucovorin and epirubicin
regimen.
Table 3 Toxicities
WHO Grade 1 2 3 4
Anaemia 22 (62%) 10 (29%) 3 (9%) —
Neutropaenia 17 (49%) 14 (40%) 4 (11%) —
Thrombocitopenia 23 (65%) 11 (32%) 1 (3%) —
Anorexia 24 (68%) 11 (32%) — —
Nausea 22 (62%) 13 (38%) — —
Vomiting 21 (60%) 14 (40%) — —
Diarrhoea 19 (54%) 14 (40%) 2 (6%) —
Stomatitis 24 (68%) 11 (32%) — —
Neurotoxicity 20 (56%) 13 (38%) 2 (6%) —
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patients, respectively. As L-OHP-related acute peripheral neuro-
pathy was generally mild, short-lived and completely reversible
within a few hours, treatment was not discontinued. Cumulative
sensory neurotoxicity was present only in 6% of patients.
Furthermore, L-OHP-induced neurotoxicity was reversible, with
a median time to recovery of 12 weeks from grade 3 toxicity. As
previously reported by De Vita et al (2005), this study confirms
that the low incidence of cumulative sensory neurotoxicity could
be related to the rather low L-OHP median cumulative dose
received by each patient (530mgm
 2).
The current study suggests that the combination therapy
L-OHP–5FU/LV–EPI is an active regimen in advanced gastric
cancer that has the advantage of being well-tolerated and more
easily administered in an outpatients setting. Further randomised
controlled studies are mandatory to compare efficacy of this
therapy with other association therapies. We do believe that the
association L-OHP–5FU/LV–EPI could improve prognosis and
the survival of patients with advanced stage gastric cancer.
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